Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Departments of Experimental Endocrinology and Pathology, University of Crete, School of Medicine, Heraklion, Crete, Greece.
Vassiliki
V
Pelekanou
George
G
Notas
Efstathios N
EN
Stathopoulos
Elias
E
Castanas
Marilena
M
Kampa
D017398:Alternative Splicing; D059002:Androgen Receptor Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D011467:Prostate / Q000187:drug effects / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011944:Receptors, Androgen / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
D059002:Androgen Receptor Antagonists; D000728:Androgens; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D020033:Protein Isoforms; D011944:Receptors, Androgen